tradingkey.logo

Mink Therapeutics Inc <INKT.OQ> expected to post a loss of 55 cents a share - Earnings Preview

ReutersAug 12, 2025 1:22 PM
  • Mink Therapeutics Inc INKT.OQ INKT.O is expected to show no change in quarterly revenue when it reports results on August 14 for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 55 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 68.7% above its last closing price of $12.22

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2025

-0.60

-0.61

-0.70

Missed

-14.8

Dec. 31 2025

-0.50

-0.62

Missed

-24

Sep. 30 2024

-0.80

-0.80

-0.50

Beat

37.5​

Jun. 30 2024

-0.98

-1.00

-0.70

Beat

30

​​Mar. 31 2024

-1.58

-1.53

-1.10

Beat

28.3

Dec. 31 2023

-1.53

-1.60

Missed

-4.3​

Sep. 30 2023

-1.79

-1.82

-1.50

Beat

17.8

Jun. 30 2023

-1.91

-1.97

-1.80

Beat

8.9

This summary was machine generated August 12 at 13:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI